EUCTR2005-001256-20-IT进行中（未招募）不适用
A randomized, double blind, double dummy, parallel group, placebo controlled study to evaluate the pharmacodynamic and pharmacokinetic response and safety and tolerability of SB424323 250mg, 375mg and 500mg administered twice daily for 16 weeks, on top of aspirin 325mg, qd in men and women with non valvular atrial fibrillation at a low or intermediate risk for stroke
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 750
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A randomized, double blind, double dummy, parallel group, multicenter clinical trial to evaluate the safety and clinical and microbiologic efficacy of oral fosfomycin calcium in adult women with uUTI.ncomplicated cysititis in womenEUCTR2021-002911-72-ESaboratorios ERN, S.A.384
进行中（未招募）
不适用
A randomized, double blind, double dummy, parallel group,placebo controlled study to evaluate the pharmacodynamic andpharmacokinetic response and safety and tolerability ofSB424323 (250 mg, 375 mg and 500 mg) administered twicedaily for 16 weeks, on top of aspirin (325 mg, qd) in men andwomen with non valvular atrial fibrillation at a low orintermediate risk for strokeStroke Prevention in Non-valvular Atrial FibrillationMedDRA version: 7.1Level: LLTClassification code 10042244EUCTR2005-001256-20-GBGlaxoSmithKline Research and Development Ltd.640
进行中（未招募）
不适用
A randomized, double blind, double dummy, parallel group,placebo controlled study to evaluate the pharmacodynamic andpharmacokinetic response and safety and tolerability ofSB424323 (250 mg, 375 mg and 500 mg) administered twicedaily for 16 weeks, on top of aspirin (325 mg, qd) in men andwomen with non valvular atrial fibrillation at a low orintermediate risk for strokeon-valvular Atrial FibrillationEUCTR2005-001256-20-EEGlaxoSmithKline Research and Development Ltd.640
进行中（未招募）
不适用
A randomized, double blind, double dummy, parallel group,placebo controlled study to evaluate the pharmacodynamic andpharmacokinetic response and safety and tolerability ofSB424323 (250 mg, 375 mg and 500 mg) administered twicedaily for 16 weeks, on top of aspirin (325 mg, qd) in men andwomen with non valvular atrial fibrillation at a low orintermediate risk for strokeon-valvular Atrial FibrillationEUCTR2005-001256-20-HUGlaxoSmithKline Research and Development Ltd.640
进行中（未招募）
不适用
A randomized, double blind, double dummy, parallel group,placebo controlled study to evaluate the pharmacodynamic andpharmacokinetic response and safety and tolerability ofSB424323 (250 mg, 375 mg and 500 mg) administered twicedaily for 16 weeks, on top of aspirin (325 mg, qd) in men andwomen with non valvular atrial fibrillation at a low orintermediate risk for strokeStroke Prevention in Non-valvular Atrial FibrillationMedDRA version: 7.1Level: LLTClassification code 10042244EUCTR2005-001256-20-LVGlaxoSmithKline Research and Development Ltd.640